Effect of expressions of adenovirus-mediated RNA interfering with ERCC1 genes on sensitivity of DDP in ovary carcinoma

TIAN Lina; QU Quanxin; SHENG Xiaobin; XU Fuqiang

PDF(2047 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2018, Vol. 29 ›› Issue (4) : 361-366.

ORIGINAL ARTICLES

Effect of expressions of adenovirus-mediated RNA interfering with ERCC1 genes on sensitivity of DDP in ovary carcinoma

TIAN Lina¹, QU Quanxin², SHENG Xiaobin¹, XU Fuqiang¹

Author information +

History +

Abstract

Objective To study the enhancement of sensitivity of DDP in ovary carcinoma by expressions of adenovirus-mediated RNA that interferes with ERCC1 genes.Methods SKOV3 cells were infected by direct infection methods and with recombinant adenovirus. Taipan blue dye, MTT, Hoechst staining and flow cytometer were used to draw SKOV3 cell growth curves and doubling time. DDP’sIC50, apoptosis morphology and the cell cycle distribution of ovary carcinoma cell line SKOV3 before and after the recombinant adenovirus infection were detected.Results (1) There was a linear positive correlation between the concentration of DDP and the cell inhibition rate of SKOV3, and the correlation coefficient r=0.9905(P<0.05), while DDP’sIC50 was (7.76±0.37)μg/ml.Ad-HTERT-ERCC1-siRNA had some inhibitory effect on SKOV3.(2)Drug sensitivity test showed that apoptosis of SKOV3 cells increased with the infectious viral titer and the concentration of DDP, and that cell survival rate significantly decreased in a dose-dependent manner.(3)As the infectious viral titer and the concentration of DDP were increased, the cell apoptosis was significantly elevated.(4)The recombinant adenovirus expression vector could increase S stage and cell apoptosis, but decrease G1 stage predominantly.Conclusions The recombinant adenovirus expression vector can effectively enhance DDP’s sensitivity to SKOV3 by inducing the apoptosis of tumor cells and regulating the cycle distribution of tumor cells.

Key words

ovarian carcinoma / ERCC1 gene / RNA interference / recombinant adenovirus expression vector

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

TIAN Lina, QU Quanxin, SHENG Xiaobin, XU Fuqiang. Effect of expressions of adenovirus-mediated RNA interfering with ERCC1 genes on sensitivity of DDP in ovary carcinoma[J]. Medical Journal of the Chinese People Armed Police Forces. 2018, 29(4): 361-366

References

[1] 刘微, 毕秋英,瞿全新,等.带hTERT启动子的腺病毒干扰ERCC1基因表达逆转卵巢癌顺铂耐药的研究[J]. 现代妇产科进展, 2012,21(4):246-249,254.
[2] 阮和云,黎丹戎,李力,等.卵巢上皮性癌淋巴道定向高转移细胞系的建立及其生物学特性的鉴定[J].中华妇产科杂志, 2007,42(7):482-486.
[3] 刘国艳,瞿全新,糜若然,等.核苷酸切除修复交叉互补基因1与卵巢癌顺铂耐药的关系[J].中华肿瘤杂志, 2008,30(3):184-187.
[4] 刘萍萍,张灿珍,王羽丰.洛铂诱导顺铂耐药卵巢癌SKOV3/DDP细胞的凋亡[J].肿瘤防治研究, 2007,34(11):829-832.
[5] 刘素华.大黄素-8-O-β-D-葡萄糖苷对人卵巢癌细胞系SKOV3细胞凋亡及Bcl-2表达的影响[J].中华医学杂志, 2015, 95(43): 3541-3544.
[6] 陈佳,王琪,张玮,等.下调MTRR基因表达对顺铂耐药的卵巢上皮性癌SKOV3细胞体内外生物学特性的影响[J].中华妇产科杂志, 2016,51(2):126-134.
[7] 王广洲,秦闫燕,卢洁,等. miR-1271对卵巢癌SKOV3/DDP细胞顺铂耐药的影响及其机制[J].江苏大学学报(医学版), 2017, 27(2): 118-122.
[8] 马焱,瞿全新,张秀艳. 腹腔热化疗中卵巢癌细胞对顺铂敏感性影响的体外研究[J].中国肿瘤临床, 2010, 37(20): 1153-1156.
[9] 李渊渊,何华,曾飚,等. 错配修复基因hMLH1和hMSH2的表达与人卵巢癌顺铂耐药的关系[J].中国肿瘤临床, 2011,38(15):875-881.
[10] 雷婷,秦宜德,刘琛,等.RNA干扰ERCC1基因表达对人卵巢癌耐药细胞 DDP、PGPIPN敏感性的影响[J].安徽医科大学学报, 2015,50(6):730-734.
[11] 刘晓玲,唐文如,罗瑛.DNA修复与肿瘤的耐药[J].生命的化学, 2012,32(6):526-533.
[12] 郑国娜.ERCC1、ERCC2、ERBB1、ERBB2、P53在膀胱尿路上皮癌中的表达及意义[D],石家庄: 河北医科大学,2016.
[13] 王娇,孙宏伟,柳星,等.ERCC1和 TS 表达对胃癌术后患者改良FOLFOX7方案辅助化疗疗效的预测[J].实用肿瘤学杂志, 2014,28(3):233-238.
[14] 姚雯航,杨紫伟,郭科军.切除修复交叉互补基因1与卵巢癌发病的相关性[J].现代肿瘤医学, 2017, 25(11): 1767-1769.
[15] 徐向勇,许平,王旭,等. ERCC1基因多态性和蛋白表达与晚期非小细胞肺癌的TP化疗疗效关系的研究[J]. 检验医学与临床, 2017, 14(9): 1233-1235.
[16] Mathilde G B, Pierre R, Anne C. ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis[J]. J Pathol Clin Res, 2016, 2(4): 234-246.
[17] 王凌.耐药相关性基因多态性与卵巢癌铂类药物关系及临床预后的研究[D].西宁: 青海大学,2016.
[18] 曾超,张昌庆.结直肠癌ERCC1、TP及GADD45A 表达与新辅助化疗疗效的关系[J].现代医药卫生, 2017,33(11):1632-1634.
[19] Hamilton G, Rath B. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1[J].Expert Opin Drug Metab Toxicol, 2018,14(1):17-24.